Tokyo, Aug. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062409) titled 'Emotional and Social Experiences of Antifibrotic (AF) Therapy among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study' on Aug. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Boehringer Ingelheim Co., Ltd.
Condition:
Condition - Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - What are the attitudes toward and experiences of the emotional and/or social impact of side effects associated with AF treatment among Japanese patients with IPF/PPF, and how are these attitudes associated with patients' individual characteristics?
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - -Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks
-Patients capable of responding to a self-administered questionnaire
Key exclusion criteria - -Patients treated with nerandomilast (including clinical trials)
-Patients with PPF treated with pirfenidone
-Patients currently hospitalized
-Patients with malignant tumors
Target Size - 135
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 07 Month 10 Day
Date of IRB - 2026 Year 07 Month 21 Day
Anticipated trial start date - 2026 Year 08 Month 01 Day
Last follow-up date - 2026 Year 09 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071417
Disclaimer: Curated by HT Syndication.
